Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success
Drug Maker Refiles PCSK9 Inhibitor Leqvio After December CRL
The company has said coverage under medical benefit could mean $0 copays for many patients, potentially overcoming a hurdle to uptake in the biologic cholesterol market.
